Scholarlink

Background <p>Adenocarcinomas often exhibit a poor response to immunotherapy due to their "cold tumor" nature and immunosuppressive microenvironment. Cancer-testis antigens (CTAs), which are selectively expressed in tumors but absent in most normal tissues, represent ideal targets for tumor-specific therapies. Despite promising individual CTAs like MAGE-A, MSLN, and PRAME, a systematic analysis of their role across various adenocarcinomas is lacking.</p> Methods <p>In this study, we explored the expression profiles, prognostic significance, and immunomodulatory roles of cancer-testis antigens (CTAs) across various types of adenocarcinomas. By integrating data from The Cancer Genome Atlas (TCGA) with a validation cohort of 198 patients, comprising cases of colon, rectal, and lung adenocarcinomas, we analyzed six CTAs (CT83, MAGEA1, MAGEA4, MAGEA10, MSLN, and PRAME) utilizing survival analysis and immunohistochemistry techniques.</p> Results <p>Our findings revealed that CTAs exhibit tumor type-specific expression profiles. Notably, MSLN was highly expressed in colon adenocarcinoma (COAD, 73%), rectal adenocarcinoma (READ, 69%), and lung adenocarcinoma (LUAD, 72%), whereas PRAME was exclusively expressed in LUAD (24%). Elevated levels of CT83 (<i>p</i> = 0.026) and MAGEA10 (<i>p</i> = 0.036) in COAD, MAGEA1 (<i>p</i> = 0.028) in READ, MAGEA1 (<i>p</i> = 0.008) and MAGEA4 (<i>p</i> = 0.009) in LUAD, were significantly associated with shorter progression-free survival (PFS). Additionally, exploratory CTA-count analysis showed that the prognostically relevant cutoff differed across tumor types, with more than one CTA-positive marker associated with poorer progression-free survival in COAD and more than two CTA-positive markers associated with poorer progression-free survival in READ and LUAD (COAD: <i>p</i> = 0.008; READ: <i>p</i> = 0.012; LUAD: <i>p</i> = 0.045). In LUAD, CT83 and MAGEA1 expression were significantly associated with lower infiltration of B cells, CD4 + T cells, and dendritic cells (all <i>p</i> &lt; 0.01), and with higher infiltration of immunosuppressive myeloid-derived suppressor cells (MDSCs, <i>p</i> &lt; 0.001) and FOXP3 + regulatory T cells (Tregs, <i>p</i> &lt; 0.05). These effects were corroborated in the validation cohort of COAD (MAGEA4-Tregs, <i>p</i> &lt; 0.05) and LUAD (CT83-Tregs, <i>p</i> &lt; 0.05).</p> Conclusions <p>We found that CTA expression was highly tumor-type-specific in adenocarcinomas. These findings provide preliminary evidence for the potential relevance of CTA-based stratification in adenocarcinomas and may inform future mechanistic studies and prospective evaluation of precision immunotherapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cancer-testis antigens as prognostic biomarkers and immune modulators in adenocarcinomas

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月9日

查看全文
  • Xin Zhang,
  • Tingting Chen,
  • Lei Lei,
  • Haorui Zhang,
  • Fangcen Liu,
  • Xiao Wei,
  • Chaoshan Wang,
  • Linyue Zhao,
  • Zhao Xiao,
  • Yuqing Li,
  • Qi Sun,
  • Xiangshan Fan,
  • Lin Li

摘要

Background

Adenocarcinomas often exhibit a poor response to immunotherapy due to their "cold tumor" nature and immunosuppressive microenvironment. Cancer-testis antigens (CTAs), which are selectively expressed in tumors but absent in most normal tissues, represent ideal targets for tumor-specific therapies. Despite promising individual CTAs like MAGE-A, MSLN, and PRAME, a systematic analysis of their role across various adenocarcinomas is lacking.

Methods

In this study, we explored the expression profiles, prognostic significance, and immunomodulatory roles of cancer-testis antigens (CTAs) across various types of adenocarcinomas. By integrating data from The Cancer Genome Atlas (TCGA) with a validation cohort of 198 patients, comprising cases of colon, rectal, and lung adenocarcinomas, we analyzed six CTAs (CT83, MAGEA1, MAGEA4, MAGEA10, MSLN, and PRAME) utilizing survival analysis and immunohistochemistry techniques.

Results

Our findings revealed that CTAs exhibit tumor type-specific expression profiles. Notably, MSLN was highly expressed in colon adenocarcinoma (COAD, 73%), rectal adenocarcinoma (READ, 69%), and lung adenocarcinoma (LUAD, 72%), whereas PRAME was exclusively expressed in LUAD (24%). Elevated levels of CT83 (p = 0.026) and MAGEA10 (p = 0.036) in COAD, MAGEA1 (p = 0.028) in READ, MAGEA1 (p = 0.008) and MAGEA4 (p = 0.009) in LUAD, were significantly associated with shorter progression-free survival (PFS). Additionally, exploratory CTA-count analysis showed that the prognostically relevant cutoff differed across tumor types, with more than one CTA-positive marker associated with poorer progression-free survival in COAD and more than two CTA-positive markers associated with poorer progression-free survival in READ and LUAD (COAD: p = 0.008; READ: p = 0.012; LUAD: p = 0.045). In LUAD, CT83 and MAGEA1 expression were significantly associated with lower infiltration of B cells, CD4 + T cells, and dendritic cells (all p < 0.01), and with higher infiltration of immunosuppressive myeloid-derived suppressor cells (MDSCs, p < 0.001) and FOXP3 + regulatory T cells (Tregs, p < 0.05). These effects were corroborated in the validation cohort of COAD (MAGEA4-Tregs, p < 0.05) and LUAD (CT83-Tregs, p < 0.05).

Conclusions

We found that CTA expression was highly tumor-type-specific in adenocarcinomas. These findings provide preliminary evidence for the potential relevance of CTA-based stratification in adenocarcinomas and may inform future mechanistic studies and prospective evaluation of precision immunotherapeutic strategies.